ReST Therapeutics Announces FDA Acceptance of IND Application for RST-101 in Early PTSD Treatment
ReST Therapeutics Receives FDA IND Clearance for PTSD Therapy RST-101 ReST Therapeutics announced that the U.S. Food and Drug Administration has accepted the company’s Investigational New Drug (IND) application for…
Otsuka Pharmaceutical Presents New Phase 3 Centanafadine ADHD Data at the ASCP Annual Meeting
Otsuka Pharmaceutical Development & Commercialization Presents New Phase 3 Centanafadine Analyses Highlighting Broader ADHD Symptom Improvements Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization unveiled new post hoc…
Draig Therapeutics Showcases Positive Phase 1 DT-101 Data at ASCP Annual Meeting
Draig Therapeutics Highlights Positive Phase 1 DT-101 Results at ASCP Annual Meeting American Society for Clinical Psychopharmacology served as the stage for new clinical and translational data from Draig Therapeutics,…
BeOne Medicines Reports Phase 3 HERIZON-GEA Results Published in NEJM and Featured at ASCO 2026
BeOne Medicines Reports Phase 3 HERIZON-GEA Results Published in NEJM and Featured at ASCO 2026 BeOne Medicines has announced the publication and upcoming presentation of significant new clinical data from…
PharmaEssentia Names Eric Vogel as U.S. Commercialization Head Ahead of Potential BESREMi® Launch in Essential Thrombocythemia
PharmaEssentia Names Eric Vogel as U.S. Commercialization Head in Preparation for Potential BESREMi® Launch in Essential Thrombocythemia PharmaEssentia Corporation has announced the appointment of Eric Vogel as the company’s new…
Secretome Therapeutics Raises $30 Million Series A to Advance STM-01 for Duchenne Cardiomyopathy
Secretome Therapeutics Secures $30 Million Series A Financing Led by RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathy Secretome Therapeutics has announced the successful completion of a $30 million…
Cosm Medical Signs Collaboration Deal to Advance Personalized Gynethotics™ Recovery Devices
Cosm Medical Enters Licensing and Collaboration Agreement to Advance Personalized Gynethotics™ Devices for Post-Surgical Pelvic Recovery Cosm Medical Corp. has announced a new licensing and collaboration agreement with Duke Health…
Stallergenes Greer Foundation Honors Leaders in Allergy Innovation with 2025 Awards
Stallergenes Greer Foundation Honors Advances in Allergy Innovation Through 2025 Award Program Stallergenes Greer Foundation has announced the recipients of its 2025 Science Awards for Allergy, recognizing four researchers whose…
New Headache Research Highlights Emerging Treatments, Biomarkers, and Gut-Brain Connections at AHS 2026
New Research on Headache Treatments, Biomarkers, and the Gut-Brain Connection to Be Featured at the American Headache Society® 68th Annual Scientific Meeting American Headache Society is preparing to host its…
Daiichi Sankyo Europe Highlights Patient-Focused Innovation with Broad Data Presentation at EAS Congress 2026
Daiichi Sankyo Europe Highlights Broad EAS Congress 2026 Data Presentations Supporting Patient-Centred Cardiovascular Care Daiichi Sankyo Europe has announced a major scientific presence at the upcoming European Atherosclerosis Society Congress…
LINZESS Receives FDA Approval for Functional Constipation Treatment in Children Aged 2 and Older
LINZESS® (linaclotide) Receives FDA Approval for Children Aged 2 and Older with Functional Constipation Ironwood Pharmaceuticals has announced that the U.S. Food and Drug Administration has approved an expanded indication…
Arrowhead Pharmaceuticals Reports Positive Cardiometabolic Data at EAS 2026
Arrowhead Pharmaceuticals Unveils Encouraging Clinical Cardiometabolic Findings at the 94th European Atherosclerosis Society Congress Arrowhead Pharmaceuticals has presented new clinical findings supporting the broader use of plozasiran, its investigational small…